First baby born in Scotland using new ground-breaking IVF technology
MENLO PARK, CA, June 14, 2013 /CNW/ - Auxogyn announces the birth of the
first baby born in Scotland at the Glasgow Centre for Reproductive
Medicine (GCRM) using a ground-breaking new approach to IVF, the 'Early Embryo
Viability Assessment' (Eeva™) test, that improves embryo selection.
View video of conception
Scotland is welcoming Baby Eva today, the world's first baby to be born
and named by her parents after the new Eeva test. Eva was born on 11th June following Susan Walker-Dempster and David Dempster's hardship of
trying to build a family together. Susan and David chose to have the
Eeva test at the GCRM to increase their chances of IVF success. The new
mother, Susan said "we wanted every chance to be successful, so we
The Eeva test uses unique predictive software in combination with a
time-lapse analysis technique to automatically analyse embryo
development against scientifically and clinically validated
cell-division parameters. The test aids embryologists in selecting the
most viable embryos for transfer, potentially increasing the chances of
a successful IVF cycle.
"We are delighted to hear the news of this healthy birth and wish the
family the very best," said Lissa Goldenstein, President and CEO of
Auxogyn. "The Eeva test has been developed to give IVF clinicians
objective information about the embryo and provide insight into its
growth potential. With more couples choosing to use Eeva, we are
looking forward to many more births like Baby Eva today."
Scientist Professor Richard Fleming at GCRM said: "We are very proud to
be among the first clinics in the world to announce this news as it
demonstrates how successful this new technology can be in enabling
couples to have a higher chance of conceiving a baby with IVF. GCRM has
always strived to be one of the leading IVF Centres in Europe, offering
couples the latest innovations and best possible outcomes. The Eeva
test is the practical end point of good quality research and is the
start of a new chapter in the evolution of IVF."
Infertility affects one out of every 6 couples and about 7.3 million
women and their partners in the U.S.. The demand for assisted
reproduction tools and procedures is growing worldwide. This growth is
occurring despite the significant cost per IVF cycle and the low
success rate, with approximately one-third of cycles resulting in a
live birth. This necessitates the transfer of multiple embryos and/or
conducting multiple cycles, leading to greater physical, emotional,
practical and financial costs, before determining if pregnancy can be
About the Early Embryo Viability Assessment (Eeva) Test
The Eeva test provides IVF clinicians with predictive information about
the embryo's development potential to help improve embryo selection.
Eeva's proprietary software automatically analyzes embryo development
against scientifically and clinically validated cell-division
parameters conceived by researchers at Stanford University in the US.
With results from the Eeva test, IVF teams now have predictive and
objective information to combine morphological assessment to help
improve the embryo selection decision. The Eeva Test was validated in a
prospective, multi-centre, 54-patient clinical trial with 758 embryos.
Embryologists using Eeva were significantly able to improve their
ability to identify non-viable embryos relative to traditional methods
alone. Additionally, Eeva was able to increase the consistency of
embryo assessment across embryologists. Results of this study were
presented in July 2012 at the European Society of Human Reproduction
and Embryology (ESHRE) Annual Meeting and published by Conaghan et al
in Fertility and Sterility, May 2013.
Eeva is currently CE Marked and available for use in the EU and is
pending FDA clearance in the United States. For a full list of clinics offering the Eeva test please visit http://www.eevaivf.com or follow us on Twitter @EevaIVF.
Auxogyn is revolutionising the field of reproductive medicine by
translating scientific discoveries in early embryo development into
clinical tools. The Company's flagship product, the Eeva™ Test,
delivers consistent, objective information regarding embryo viability
that IVF clinicians and patients can use to make important treatment
decisions. Auxogyn is privately held and funded by Kleiner Perkins
Caufield & Byers, Merck Serono Ventures, SR One and TPG Biotech. For
more information visit http://www.auxogyn.com and follow us on Twitter @Auxogyn.
For further information:
Sylvie Berrebi: email@example.com +44-(0)-7795-197271
Richard Anderson: firstname.lastname@example.org +44-(0)-7973-950376